Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
about
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cellsPI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cellsKinase inhibitors as potential agents in the treatment of multiple myeloma.Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonTargeting the PI3K signaling pathway in KRAS mutant colon cancer.Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction.Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
P2860
Q34502870-029C88D2-6F1B-4EB8-A107-59B006C58709Q35146479-082F20D2-A17D-43F0-BDA9-B9CD19DBAFE2Q35832168-2B7BD329-5454-4699-BC7D-C09AC92E006CQ35849961-198AD4A3-EE98-4DBA-A9C1-15DB0DDC9FFFQ36379644-585656EF-7245-431F-A330-FB8ECFEC3908Q36414426-92AFAA67-F4B1-48A4-BE18-0B3DBD3B8F4BQ36485168-2434AD67-DDC5-4030-A6F6-C23912E074B8Q37252398-58EC78A4-2483-4FED-8D02-FD1B56470430Q37350230-68A9A177-68C7-42EC-8D0B-64133E8056A1Q37353724-AB2119C6-7EC7-49BF-BE87-6E97B0466DF1Q37687154-62627C8C-E38D-4F39-B215-E5CD44A3BEE7Q37697253-9C07A95E-FA3D-466F-A1C1-D900E402E93BQ38193070-6565D1A9-254C-475B-A04E-4956C25E19C1Q38478630-7D3E36F7-E803-4F59-9EE0-19C75F363250Q38808155-83A28113-0726-4DC5-8AC8-679D96B9745CQ38957093-8E482AC1-3876-40D6-96A5-9FB1AADFC857Q38971845-357D1E92-105B-41B4-9622-5FAC66116AC5Q39036088-924A727C-7680-47EB-8AB5-EDF76473605AQ39145770-C20D66FE-36A6-4872-83D2-87056207EF01Q39170414-D126F284-1132-4A13-BB8C-80F82BDDD4F5Q39317004-964EE402-1F21-4DFC-AFC3-02CE689491B9Q42924738-126DDB6D-4A7C-4613-AEE6-9F6659CF394AQ44498168-88A877BA-4ADC-409A-ACCF-A5655B87A48AQ47141630-8DA6C75E-38D9-414A-A669-B531836B49ECQ52363953-5746AA00-FB6C-41DB-A439-12A81BAB3C11Q52649710-A65E59C9-EAA4-4673-9A25-27605B878390Q52687754-E9FF30B1-B38A-49DC-955E-F8729DF7D8ADQ52859066-01A039CC-E12F-48DF-BE1B-777B61267CA6
P2860
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@ast
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@en
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@nl
type
label
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@ast
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@en
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@nl
prefLabel
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@ast
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@en
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@nl
P2093
P2860
P1476
Novel phosphatidylinositol 3-k ...... a activity with dexamethasone.
@en
P2093
Heather Lin
Jatin Shah
Jianfei Qian
Larry W Kwak
Liang Zhang
Sheeba Thomas
P2860
P2888
P304
P356
10.1007/S00109-011-0849-9
P577
2011-12-30T00:00:00Z
P6179
1029444253